BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCryst projects $1B peak sales for ORLADEYO, eyes global expansion

BioCryst Pharmaceuticals showcased strong performance driven by ORLADEYO's success, with a clear path towards $1 billion in peak sales and global expansion.
While facing challenges such as delays in BCX10013's development and managing expenses, the company remains focused on maximizing product value and market opportunities.
Opportunities lie in expanding ORLADEYO's market presence, exploring international sales, and investing in R&D for future growth and innovation.

BioCryst projects strong revenue growth for ORLADEYO, faces regulatory hurdles

BioCryst Pharmaceuticals demonstrates strong performance and revenue growth potential for ORLADEYO, aiming to exceed $320 million guidance for the year.
Challenges include revenue impact from free drug complexities and regulatory delays, with opportunities in global market expansion and pediatric therapy development.
The company's focus on patient care, financial stability, and long-term sales outlook positions BioCryst for continued growth and success in the pharmaceutical market.

BioCryst Pharmaceuticals on track to hit $320M in ORLADEYO sales

BioCryst Pharmaceuticals is confident in reaching $320 million in ORLADEYO sales this year through patient growth. Q3 and Q4 revenue growth expected to be steady, with opportunities for expansion outside the U.S.

BioCryst's ORLADEYO excels in Q3, faces challenges and growth opportunities

BioCryst Pharmaceuticals continues to see strong performance with ORLADEYO revenue and patient growth.
The company faces challenges with co-payment assistance programs and competitive market dynamics.
Opportunities lie in market education, pediatric patient expansion, and maintaining a competitive edge.
Despite expected expense increases, BioCryst remains focused on value creation and long-term growth.

BioCryst reports robust earnings, eyes $1B peak revenue for ORLADEYO

BioCryst Pharmaceuticals showcased strong financial performance and positive long-term data for ORLADEYO, aiming for $1 billion in global peak revenue.
While facing challenges with patient retention and market access, the company emphasized its growing product portfolio and accelerated path to profitability.
Opportunities lie in achieving profitability by 2026, improving market access, and leveraging therapy efficacy to drive revenue growth and market expansion.

BioCryst Pharmaceuticals excels in Q1, eyes Japanese market expansion

BioCryst Pharmaceuticals delivered strong Q1 results driven by ORLADEYO sales, raising revenue guidance for 2024 and advancing pipeline programs.
While facing challenges in expenses and gross to net margins, the company's strategic focus on market expansion and pipeline development presents growth opportunities.
Overall, BioCryst Pharmaceuticals shows promise with a balanced patient mix, strong market research projections, and high strategic interest in its flagship product.

BioCryst's ORLADEYO excels, revenue guidance raised amidst operational achievements

BioCryst Pharmaceuticals showcased robust performance in Q2 driven by ORLADEYO, with strong revenue growth and operational achievements.
Despite challenges like product portfolio diversification and profitability targets, the company's strategic focus on ORLADEYO's market expansion and revenue guidance increase highlights growth potential.
Opportunities lie in further leveraging ORLADEYO's success, exploring new market segments, and enhancing market strategies to drive sustained growth and market leadership.

BioCryst Pharmaceuticals reports robust revenue growth and pipeline advancements

BioCryst Pharmaceuticals delivered strong financial results driven by ORLADEYO's performance, showcasing market acceptance and revenue growth.
The company's pipeline advancements and proactive management approach position them well for future growth and product portfolio expansion.
While facing challenges in sustaining momentum and managing competition, BioCryst Pharmaceuticals has opportunities to capitalize on market demand and optimize operational strategies for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

RESEARCH TRIANGLE PARK, N.C., April  09, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. The trial (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19

AbbVie

Gilead Sciences

Regeneron Pharmaceuticals

Roche Holding AG

Biotech Companies In The Race To Find COVID-19 Treatment

BioCryst Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

BioCryst Sees Hammer Chart Pattern: Time to Buy?

RESEARCH TRIANGLE PARK, N.C., April  03, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees options to purchase an aggregate of 286,000 shares of BioCryst common stock on March 31, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

BioCryst Reports Inducement Grants  Under Nasdaq Listing Rule 5635(c)(4)

The company, which is developing a drug that could treat the coronavirus, has named a corporate veteran to head its finance team.

BioCryst Appoints New CFO

RESEARCH TRIANGLE PARK, N.C., April  02, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Anthony Doyle as senior vice president and chief financial officer (CFO).

BioCryst Appoints Anthony Doyle Chief Financial Officer

AcelRx Pharmaceuticals

BuildABear

CACI

Evercore

After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as well.

After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys

RESEARCH TRIANGLE PARK, N.C., March  30, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) submission for approval of oral, once-daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.

European Medicines Agency Validates Marketing Authorization Application for Oral, Once-Daily Berotralstat (BCX7353) to Prevent HAE Attacks

BioCryst: Take Advantage Of Current Extreme Volatility To Buy At Bargain Prices

RESEARCH TRIANGLE PARK, N.C., March  16, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data from the APeX-2 trial showing 150 mg of oral, once-daily berotralstat (BCX7353) for prophylaxis of hereditary angioedema (HAE) attacks reduced patients’ monthly use of standard of care (SoC) on-demand medicine by 53.6 percent (p

BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2

Artisan Partners Asset Management

Calix

Molecular Templates

Orion Energy Systems

Superior Energy Services

Trinity Industries

Take advantage of panic selling with these 7 cheap stocks.

7 Great Stocks for a Small Budget

BioCryst Pharmaceuticals: Multiple Value Drivers With A Coronavirus Kicker

The FDA is reviewing the biotech's marketing application for its hereditary angioedema treatment berotralstat.

BioCryst Looks for FDA Approval in Late 2020, Launches Next Clinical Trial

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2019 Results - Earnings Call Transcript

Hint: It got some help from a big partner in Japan.

How BioCryst Pharmaceuticals Blew Away Expectations in Q4

Alpha Pro Tech

Co-Diagnostics

GenMark Diagnostics

These companies have different products related to the coronavirus outbreak but share one thing in common: Their stocks are all rising.

Why These 4 Coronavirus-Focused Stocks Are Soaring Today

Data from proof of concept trial expected in 2Q 2020 Data from proof of concept trial expected in 2Q 2020

BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930

RESEARCH TRIANGLE PARK, N.C., March  02, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees options to purchase an aggregate of 333,000 shares of BioCryst common stock on February 28, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

BioCryst Reports Inducement  Grants Under Nasdaq Listing Rule 5635(C)(4)

BioCryst Pharmaceuticals: BCX9930 Results In PNH Patients An Important Near-Term Catalyst

BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher

BioCryst's Berotralstat In Japan: A Guaranteed Commercial Success

Inovio Pharmaceuticals

Moderna

Novavax

These five biotechs are likely to remain on the volatile side this week, thanks to the novel-coronavirus threat.

Could These 5 Stocks Benefit From the Coronavirus Outbreak?

B2Gold

Callon Petroleum

Cemex SAB de CV

IAMGOLD

Mizuho Financial Group

Nokia

Despite a coronavirus scare, the S&P 500 has held up relatively well do far in 2020 and is trading within a stone’s throw of all-time highs.

7 Stocks To Buy Under $5

RESEARCH TRIANGLE PARK, N.C., Feb.  06, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees options to purchase an aggregate of 140,000 shares of BioCryst common stock on January 31, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4).

BioCryst  Reports Inducement  Grants Under NASDAQ Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb.  03, 2020  (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has submitted a new drug application (JNDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA)  for approval of oral, once daily berotralstat for the prophylactic treatment of hereditary angioedema (HAE).

News for BioCryst Pharmaceuticals Stock (BCRX)